A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Aims:  The purpose of this study is to investigate the possibility of an association between NAION and the use of PDE5 inhibitors for the treatment of male erectile dysfunction (including Cialis ®, Viagra ®, Revatio ® and Levitra ®).
Diagnosis: Nonarteritic Anterior Ischemic Optic Neuropathy. Patients do not need to have taken any PDE5 inhibitors to participate.
Principal Investigator: Troy Close, MD
IRB Approval Number: EH10-345
Sponsor:  Eli Lilly, Inc.
Contact: Interested patients should contact study coordinator Mira Shiloach at 847.657.1750 or email mshiloach@northshore.org
Open to Enrollment:  Yes

Effect of Corneal Preservation Time on Long-Term Graft Success (CPTS)
Aims:Donor corneas for transplants are placed into a liquid that helps preserve the cornea until it is transplanted.  The Food and Drug Administration (FDA) has approved storage of the cornea in this liquid for up to 14 days before the transplant.  The purpose of this study is to see if the length of time the donor cornea is kept in the preservation liquid before the transplant affects the likelihood of the transplant being successful. Patients are followedfor 3 years after transplant to see if there are any differences in transplant success or in the number of transplanted endothelial cells (the layer of cells that line the undersurface of the cornea) on the corneas that were preserved for 7 days or less compared to those preserved between 8 and 14 days.
Diagnosis: Cornea dysfunction which will be treated by a corneal transplan>
Principal Investigator: Marian Macsai, MD
IRB Approval Number: EH12-151
Sponsor: National Eye Institute
Contact: Interested patients should contact study coordinator Mira Shiloach at 847.657.1750 or email mshiloach@northshore.org
Open to Enrollment: Yes

A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis (CL1104)
Aims: This study will examine the safety and efficacy of an investigational eye drop, NVC-422 ophthalmic solution 0.33%, in the treatment of adenoviral conjunctivitis (pink eye which is caused by a virus). There are currently no available treatments for adenoviral conjunctivitis.
Diagnosis: Symptoms of “pink eye” for 3 days or less. Viral conjunctivitis diagnosis is confirmed in the office using an FDA- approved screening test.
Principal Investigator: Joshua Herz, MD
IRB Approval Number: EH12-178
Sponsor:  NovaBay Pharmaceuticals, Inc.
Contact:  Interested patients should contact study coordinator Mira Shiloach at 847.657.1750 or email mmshiloach@northshore.org
Open to Enrollment:  Yes

Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Aims:  This study is being done to find out if using an injection in the eye of the drug Lucentis ® can treat Proliferative Diabetic Retinopathy as well as laser treatment (the current standard of care treatment) but with fewer side effects
Diagnosis: Proliferative Diabetic Retinopathy
Principal Investigator: Manvi Maker, MD
IRB Approval Number: EH12-071
Sponsor:  Diabetic Retinopathy Clinical Research Network
Contact:  Interested patients should contact study coordinator Mira Shiloach at 847.657.1750 or email mshiloach@northshore.org
Open to Enrollment:  No

× Alternate Text